239 related articles for article (PubMed ID: 28062698)
1. Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.
Tammen A; Derer S; Schwanbeck R; Rösner T; Kretschmer A; Beurskens FJ; Schuurman J; Parren PW; Valerius T
J Immunol; 2017 Feb; 198(4):1585-1594. PubMed ID: 28062698
[TBL] [Abstract][Full Text] [Related]
2. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen.
Wang B; Yang C; Jin X; Du Q; Wu H; Dall'Acqua W; Mazor Y
MAbs; 2020; 12(1):1690959. PubMed ID: 31829766
[TBL] [Abstract][Full Text] [Related]
3. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
Oostindie SC; van der Horst HJ; Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; VanDerMeid KR; Strumane K; Chamuleau MED; Mutis T; de Jong RN; Schuurman J; Breij ECW; Beurskens FJ; Parren PWHI; Taylor RP
Haematologica; 2019 Sep; 104(9):1841-1852. PubMed ID: 30792198
[TBL] [Abstract][Full Text] [Related]
4. Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen.
Wang G; de Jong RN; van den Bremer ET; Beurskens FJ; Labrijn AF; Ugurlar D; Gros P; Schuurman J; Parren PW; Heck AJ
Mol Cell; 2016 Jul; 63(1):135-45. PubMed ID: 27320199
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop.
Rösner T; Lohse S; Peipp M; Valerius T; Derer S
J Immunol; 2014 Aug; 193(3):1485-95. PubMed ID: 24973443
[TBL] [Abstract][Full Text] [Related]
6. Carbamylation reduces the capacity of IgG for hexamerization and complement activation.
Lubbers R; Oostindie SC; Dijkstra DJ; Parren PWHI; Verheul MK; Abendstein L; Sharp TH; de Ru A; Janssen GMC; van Veelen PA; van den Bremer ETJ; Bleijlevens B; de Kreuk BJ; Beurskens FJ; Trouw LA
Clin Exp Immunol; 2020 Apr; 200(1):1-11. PubMed ID: 31853959
[TBL] [Abstract][Full Text] [Related]
7. Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation.
van den Bremer ET; Beurskens FJ; Voorhorst M; Engelberts PJ; de Jong RN; van der Boom BG; Cook EM; Lindorfer MA; Taylor RP; van Berkel PH; Parren PW
MAbs; 2015; 7(4):672-80. PubMed ID: 26037225
[TBL] [Abstract][Full Text] [Related]
8. Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.
Cook EM; Lindorfer MA; van der Horst H; Oostindie S; Beurskens FJ; Schuurman J; Zent CS; Burack R; Parren PW; Taylor RP
J Immunol; 2016 Sep; 197(5):1762-75. PubMed ID: 27474078
[TBL] [Abstract][Full Text] [Related]
9. A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.
de Jong RN; Beurskens FJ; Verploegen S; Strumane K; van Kampen MD; Voorhorst M; Horstman W; Engelberts PJ; Oostindie SC; Wang G; Heck AJ; Schuurman J; Parren PW
PLoS Biol; 2016 Jan; 14(1):e1002344. PubMed ID: 26736041
[TBL] [Abstract][Full Text] [Related]
10. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
[TBL] [Abstract][Full Text] [Related]
11. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
12. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
Idusogie EE; Presta LG; Gazzano-Santoro H; Totpal K; Wong PY; Ultsch M; Meng YG; Mulkerrin MG
J Immunol; 2000 Apr; 164(8):4178-84. PubMed ID: 10754313
[TBL] [Abstract][Full Text] [Related]
13. Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding.
Kline JB; Fernando S; Ross EN; Grasso L; Nicolaides NC
Eur J Immunol; 2018 Nov; 48(11):1872-1882. PubMed ID: 30144039
[TBL] [Abstract][Full Text] [Related]
14. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
[TBL] [Abstract][Full Text] [Related]
15. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
Front Immunol; 2018; 9():958. PubMed ID: 29867943
[TBL] [Abstract][Full Text] [Related]
16. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
17. Structural difference in the complement activation site of human IgG1 and IgG3.
Michaelsen TE; Sandlie I; Bratlie DB; Sandin RH; Ihle O
Scand J Immunol; 2009 Dec; 70(6):553-64. PubMed ID: 19906198
[TBL] [Abstract][Full Text] [Related]
18. Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation.
Wei B; Gao X; Cadang L; Izadi S; Liu P; Zhang HM; Hecht E; Shim J; Magill G; Pabon JR; Dai L; Phung W; Lin E; Wang C; Whang K; Sanchez S; Oropeza J; Camperi J; Zhang J; Sandoval W; Zhang YT; Jiang G
MAbs; 2021; 13(1):1893427. PubMed ID: 33682619
[TBL] [Abstract][Full Text] [Related]
19. Human IgG1 monoclonal antibody against human collagen 17 noncollagenous 16A domain induces blisters via complement activation in experimental bullous pemphigoid model.
Li Q; Ujiie H; Shibaki A; Wang G; Moriuchi R; Qiao HJ; Morioka H; Shinkuma S; Natsuga K; Long HA; Nishie W; Shimizu H
J Immunol; 2010 Dec; 185(12):7746-55. PubMed ID: 21076071
[TBL] [Abstract][Full Text] [Related]
20. Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.
Engelberts PJ; Voorhorst M; Schuurman J; van Meerten T; Bakker JM; Vink T; Mackus WJ; Breij EC; Derer S; Valerius T; van de Winkel JG; Parren PW; Beurskens FJ
J Immunol; 2016 Dec; 197(12):4829-4837. PubMed ID: 27807190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
